Spironolactone diminishes urinary albumin excretion in patients with type 1 diabetes and microalbuminuria: a randomized placebo-controlled crossover study

S E Nielsen, F Persson, E Frandsen, T Sugaya, G Hess, D Zdunek, K J Shjoedt, H-H Parving, Peter Rossing

74 Citations (Scopus)

Abstract

Adding aldosterone receptor blockade to standard renoprotective treatment may provide additional renoprotection in patients with overt nephropathy. We expected an impact of spironolactone in early diabetic nephropathy, and for this hypothesis we studied the effect on markers of glomerular and tubular damage in patients with Type 1 diabetes and persistent microalbuminuria.
Original languageEnglish
JournalDiabetic Medicine
Volume29
Issue number8
Pages (from-to)e184-90
ISSN0742-3071
DOIs
Publication statusPublished - 2012
Externally publishedYes

Keywords

  • Adolescent
  • Adult
  • Aged
  • Aged, 80 and over
  • Albuminuria
  • Angiotensin Receptor Antagonists
  • Angiotensin-Converting Enzyme Inhibitors
  • Antihypertensive Agents
  • Cross-Over Studies
  • Diabetes Mellitus, Type 1
  • Diabetic Nephropathies
  • Diuretics
  • Double-Blind Method
  • Drug Therapy, Combination
  • Female
  • Glomerular Filtration Rate
  • Humans
  • Male
  • Middle Aged
  • Spironolactone
  • Treatment Outcome
  • Young Adult

Fingerprint

Dive into the research topics of 'Spironolactone diminishes urinary albumin excretion in patients with type 1 diabetes and microalbuminuria: a randomized placebo-controlled crossover study'. Together they form a unique fingerprint.

Cite this